Skip to main content
Download PDF

Functions and underlying mechanisms of miR-650 in human cancers

Cancer Cell International volume 22, Article number: 132 (2022) Cite this article

Abstract

MicroRNAs (miRNAs) are one type of noncoding RNAs that interfere with mRNA translation to downregulate gene expression, which results in posttranscriptional gene silencing. Over the past two decades, miRNAs have been widely reported to impact the progression of malignant tumours by interfering with cancer initiation and progression; therefore, miRNAs represent potential new diagnostic and therapeutic tools. miR-650 is a newly identified miR, and increasing studies have demonstrated that miR-650 plays critical roles in cancer progression, such as mediating the Wnt signalling pathway/AXIN1 (axis inhibition protein 1) axis in hepatocellular carcinoma. Nevertheless, associations between the expression patterns and molecular mechanisms of miR-650 in cancer have not been comprehensively described. In this article, we review the existing evidence regarding the mechanisms by which miR-650 expression is altered and their relation to cancer. Moreover, the promising clinical application of miR-650 for diagnosis and treatment is highlighted.

Background

Cancer is currently the major cause of death worldwide. By 2030, the number of cancer deaths is estimated to increase to 13 million [1], which will be an immense burden on the worldwide health system and especially on the health systems in low-income countries [2]. Primary cancer prevention, early detection and timely treatment are the most cost-effective to improve the prognosis and reduce the mortality of patients with cancer. Over the past few decades, great efforts have been made to reveal the molecular mechanisms of tumorigenesis, and its management has been dramatically revolutionized by accurately targeted therapies. For example, directly targeted drugs for KRAS (Kirsten rat sarcoma viral oncogene homologue), one of the most frequently mutated oncogenes, have obtained encouraging results in clinical trials [3]. Moreover, immune therapy aimed at immune checkpoints, such as inhibitors of programmed cell death protein 1 (PD-1), provides huge benefits to cancer patients [4]. Despite great improvements in diagnosis and treatment, the patient mortality associated with tumours are still a severe problem in both sexes. Hence, new molecular agents and strategies with high accuracy need to be identified and applied to the early diagnosis and effective treatment of human cancer.

As a class of endogenous and noncoding RNAs run the length of only 20–24 nt [5], miRNAs play a central role in cell proliferation and migration. By interacting with supplementary series in the 3′-untranslated regions of target mRNAs, miRNAs regulate target genes by repressing translation or degrading target mRNAs at the posttranscriptional level. In just over two decades, more than 2600 miRNAs have been uncovered, and the miR field has expanded considerably [6, 7]. Currently, increasing evidence from in vivo and in vitro experiments has revealed that miRNAs play crucial roles as multifunctional regulators of wide-ranging diseases, particularly in cancer. miRNAs are further categorized into tumour promoters and tumour suppressors [8]. For example, miR-34a, one of the best-investigated members of the miR-34 family, has been shown to play a tumour suppressive role in p53-mediated apoptosis by directly targeting the antiapoptotic protein sirtuin1 [9]. In head and neck cancer, miRNA-196a has been shown to promote cisplatin resistance by targeting (cyclin-dependent kinase inhibitor 1B (CDKN1B) [10]. Insights into the molecular mechanisms of miRNAs in cancer have made miRNAs attractive biomarkers for cancer diagnosis and novel therapeutic approaches.

In recent years, numerous studies have revealed that miR-650 plays vital roles in various tumours. miR-650 is up- or downregulated in various tumour types and can act as a tumour suppressor or oncogene. Moreover, miRNA mimics and molecules targeting miR-650 (anti-miR) have shown tremendous potential in preclinical development. One recent study reported that lncRNA MCTP1 upregulated the expression of miR-650 in endometrial cancer (EC) through the miR-650/SMAD7 axis [11] and then modulated the cell proliferation and invasion, and induced epithelial to mesenchymal transition (EMT) process of EC. Inhibitor of growth 4 (ING4) is a well-known tumour suppressor, and some reports have shown that the ING4 expression level is remarkably downregulated in tumour tissues by miR-650 [12,13,14,15,16,17,18]. miR-650 also contributes to drug resistance, such as by upregulating dacarbazine (DTIC) resistance in melanoma through the lncRNA POU3F3/miR-650/MGMT (methylguanine-DNA-methyltransferase) axis [19], which turns miR-650 into a potential target for cancer treatment. In addition, miR-650 can influence other diseases, such as rheumatoid arthritis [20, 21], ulcerative colitis, and cerebral ischaemia/reperfusion injury. In this review, we systematically summarize the expression profiles and functions of miR-650 in various tumours, with special emphasis on its target genes, upstream regulators, and interacting molecules. Furthermore, we summarize the clinical application potential of targeting miR-650 in the oncology field.

Human studies of miR-650

Initially, miR-650 was identified by Cummins et al. [22] using a miRAGE cloning approach in colorectal cells. Over the next few years, it was quickly recognized that miR-650 is conserved and has extensive functional significance throughout the plant and animal kingdoms. Data from GeneCards (https://www.genecards.org) reveal that miR-650 genes are located in the eukaryotic genome on chromosome 22. Sequence analysis and structural predictions in Das’s research [23] revealed that the miR-650 genes were emerged in multiple copies and overlapped with the leader exons of the immunoglobulin lambda variable 2–8 genes located on chromosome 22 in the same transcription orientation. Notably, the miR-650 gene is the only known miRNA gene that overlaps with immunoglobulin genes [24].

Expression of miR-650 in cancers

Hepatocellular carcinoma (HCC)

Hepatocellular carcinoma (HCC), the most frequent primary cancer, is the third major cause of tumor-related deaths [25]. It has the characteristics of a high degree of malignancy, poor treatment response and unfavourable prognosis [26] and represents a heavy public health burden. Multiple risk factors [27,28,29] involved in the complex process of HCC have been widely reported, among which miR-650 is one of the key molecules. For the past few years, dysregulation of miR-650 in HCC has been widely reported. Han et al. [30] found that miR-650 expression significantly overexpressed in HCC tissues, especially in patients with tumour metastasis. Qin’s et al. [31] research revealed that the expression of Axin, which can inhibit the progression of HCC by targeting miR-650, was weak in HCC. Moreover, the overexpression of miR-650, which can be stimulated with benzo[a]pyrene, promotes the pathological process of fatty liver disease and HCC, as implicated in the work of Ge et al. [32]. Another bioinformatic analysis also demonstrated that the relative quantification of miR-650 in liver tissue was markedly increased in non-alcoholic steatohepatitis (NASH) groups [33]. In addition, elevated miR-650 expression was significantly associated with patient differentiation capability and advanced tumour TNM stage [34]. These findings combined with the above data based on cell lines and clinical samples indicate that miR-650 functions as a tumour promoter in HCC. As discussed above, the progression of HCC is closely related to the expression of miR-650, making it a promising biomarker and therapeutic target for the early prevention and applicable treatment of HCC. Nevertheless, the antitumour effect of miR-650 has rarely been reported in HCC.

miR-650 and lung cancer (LC)

Approximately 2.2 million cases of lung cancer (LC) were newly increased in 2020. LC causes the most cancer-induced deaths (18.0% of total cancer deaths) [35], of which non-small-cell lung cancer (NSCLC) accounts for the majority [36]. Accumulating studies have indicated that miR-650 acts as a tumour promoter in LC, including NSCLC and lung adenocarcinoma (LAD). In the present study, miR-650 was shown to highly express in NSCLC. Huang et al. [16] found that the expression level of miR-650 was substantially higher in LAD tissue samples than in adjacent normal controls. Moreover, the overexpression of miR-650 was dramatically correlated with the clinical characteristics of LAD patients, such as advanced tumour stage, high incidence of lymph node metastasis, and unfavourable prognosis [16]. Furthermore, downregulation of miR-650 reversed the docetaxel resistance of LAD cells [16]. Another study demonstrated that miR-650 overexpressed in NSCLC, and in vitro experiments indicated that miR-650 promoted the cancer cell proliferation and migration, which resulted in low overall survival date of NSCLC patients [13]. Moreover, a miR-650 inhibitor was shown to attenuate si-MEG3-induced promotion of the LC stem cell-like state, migration and invasion in NSCLC [37]. In spite of great advances in diagnostic and therapeutic methods, the overall survival rate of NSCLC patients is still below 15% [38]. Thus, more efforts are needed to explore new effective strategies for the diagnosis and clinical treatment of LC.

miR-650 and colorectal cancer (CRC)

According to Global Cancer Statistics, more than 1.9 million new cases of colorectal cancer (CRC) were estimated to occur in 2020, causing 935,000 deaths globally. Tumour metastasis develops in approximately 10% of patients in stage I or II and eventually leads to death within 5 years after exsection [39]. Currently, dysregulation of miR-650 has been researched in CRC, and miR-650 has been reported to act as both a tumour promoter or suppressor; therefore, the role and function of miR-650 in CRC remain controversial. Zhou et al. [39] discovered that the expression of miR-650 in CRC tissues positively correlated with the overall survival of patients. Furthermore, it repressed high-risk non-metastatic CRC progression [39] by inhibiting cell growth and invasion. In contrast, some reports have shown that miR-650 is upregulated and functions as an oncogene in CRC [14, 40,41,42]. Based on what we already know, there is seemingly no consensus about the expression and function of miR-650 in CRC progression. Thus, more research is needed to comprehensively explore the roles of miR-650 in CRC.

miR-650 and gastric cancer (GC)

Gastric cancer (GC) was responsible for approximately 769,000 deaths in 2020, ranking fourth in mortality and fifth in incidence [43] globally. Due to the diagnosis of GC at early stages with complications, limited treatment options and poor prognoses, GC remains a great clinical challenge [44]. At present, the standard diagnostic methods for GC patients are gastroscopy and biopsy, but the utility of these methods is limited largely due to the invasiveness of GC and limited medical resources [45]. miR-650, as a new tumour biomarker in GC, has been investigated in recent years. One bioinformatic study based on 180 GC patients and 45 healthy individuals indicated that elevated miR-650 expression levels was significantly correlated with the existence of GC [45] and miRNA-650 are evaluated to be a promising and powerful non-invasive biomarker for the detection of GC. Previously, Zhang et al. [15] reported that overexpression of miR-650 promoted GC tumorigenesis in vivo and GC cell clonogenicity in vivo. Moreover, the overexpression of miR-650 has a positively association with the advancement of GC, as demonstrated in the work of Liu et al. [46] and An et al. [47].

miR-650 and glioma

Glioma, the most common primary tumour in the brain, accounts for approximately one-third of malignant cancers of the central nervous system [48]. Sun et al. [49] found that miR-650 expression was critically increased in glioma tissues and that was more frequently explored in tumours with a high WHO grade or low Karnofsky performance score (P < 0.001). Another study reported that miR-650 overexpressed in glioma tissues and cell lines. Furthermore, intensive expression was significantly correlated with the advanced tumour stage, lymph node metastasis and poor prognoses in glioma patients [50]. In contrast, Xu et al. [51] found that miR-650 was expressed at a low level in glioma tissues and in vitro cell lines.

miR-650 and melanoma

Cutaneous melanoma is a common tumour derived from the epidermis and mucosa [52]; it comprises 4-10% of all malignant cancers and is correlated with 75% of skin cancer-related deaths [53]. The death rates associated with melanoma have reportedly dropped rapidly after the introduction of new therapies, including targeted therapies for melanoma metastasis and immune checkpoint inhibitors [54, 55]. Liu et al. [56] recently found that the regulation of miR-650 has a negative correlation with melanoma progression. Moreover, further study showed that miR-650 overexpression alleviated MGMT-induced DTIC resistance in melanoma by increasing cell apoptosis [19], which indicated that miR-650 was a novel biomarker of great value for the evaluation of melanoma.

miR-650 and leukaemia

As the most frequent malignancy of the bone marrow, acute myeloid leukaemia (AML) has a high fatality rate [35]. Yuan et al. [57] revealed that miR-650 expression was reduced in AML, which contributed to leukaemia progression. Similarly, Gaine et al. [58] found that the expression of the erythropoietin receptor (EPOR) in t(12;21) B-ALL cells was higher than that in normal samples. Notably, EPOR expression is influenced by GATA2 and has an inverse correlation with miR-650 expression [58]. One study published in Blood reported that overexpression of miR-650 is correlated with a favourable chronic lymphocyte leukaemia (CLL) prognosis and affects the oncogenic capacity of B cells [24]. Furthermore, multivariate analysis showed that overexpression of miR-650 is an available independent predictor of survival and time to first treatment (TTFT) [24]. However, an inconsistent report that partly argued against the results above showed a significant increase in miR-650 expression in CLL patients [59]. Hence, the association between leukaemia and miR-650 needs further verification by expanding the number of patient samples included in the current work.

Other tumours

miR-650 has also been found to serve as an oncogene that is upregulated in various other cancers. In breast cancer, overexpression of miR-650 has been observed to induce the downregulation of the tumour suppressor ING4, which we previously mentioned is significantly correlated with EMT of breast cancer cells [60]. Another recent study revealed that the expression level of miR-650 is upregulated in EC, resulting in the progression of EC through the SMAD7-TGF-β (transforming growth factor-β) pathway [11]. In addition, miR-650 overexpressed in anaplastic thyroid carcinoma (ATC), where it promotes the proliferation and motility of cancer cells by targeting Protein Phosphatase 2 Catalytic Subunit Alpha (PPP2CA) [61]. In osteosarcoma, miR-650 has been reported to function as an oncogene. Yun et al. [18] revealed that overexpressing miR-650 decreased ING4 expression in human osteosarcoma cells and increased IL-6 transcription. Both ING-4 and IL-6 could modulate osteoblast and osteoclast differentiation. Moreover, miR-650 could upregulate the transcriptional activity of NF κB [18] and reduce the quantity of nuclear factor (NF) of κ light polypeptide gene enhancer. Interestingly, similarly significant upregulation of miR-650 has been observed in oral cancer, and the expression of miR-650 has been positively correlated with cancer cell proliferation, migration and invasion [62]. Likewise, Zuo et al. [63] reported that miR-650 could function as an onco-miR in prostate cancer by suppressing cellular stress response (CSR1) expression.

Overall, these findings have revealed that the profile of miR-650 expression depends on the type of cancer and that miR-650 is involved in the occurrence and development of various cancers. The overall expression files of miR-650 in various cancers and relative clinical features are presented in Tables 1 and 2. Even so, more studies are required to further explore the expression profiles of miR-650 in tumours.

Table 1 Expression of miR-650 in various cancer and relative clinical significance
Full size table
Table 2 The roles of miR-650 in various cancer cell lines
Full size table

Functions of miR-650 and the related mechanisms

In addition to the abberant expression files of miR-650, researchers have also observed variations in the biological functions of miR-650 through in vitro and in vivo experiments. Generally, miR-650 functions as an onco-miR or tumour suppressor by affecting biological processes such as cell proliferation and apoptosis. In the next section, we summarize the dual roles of miR-650 in tumours and the signalling pathways involved. Additionally, the comprehensive functions and related mechanisms of miR-650 in various tumours are presented in Figs. 1 and 2.

Fig. 1
figure 1

Upstream regulation of miR-650. Multiple factors participate in the upstream regulation of the miR-650 biological process. In the nucleus, transcription of miR-650 is modulated by coupling expression with its homologous gene immunoglobulin lambda and promoted by transcription factors PBX1 and NF-kB. In the cytoplasm, AXIN1 and lncRNAs (DICER-AS1, MEG3, MIR155HG, POU3F3, ZFPM2-AS1, MCTP1-AS1), which account for the major alterations, act as molecular sponges for miR-650 and negatively regulate its biological function, inducing cancer gene deregulation

Full size image
Fig. 2
figure 2

Target regulators of miR-650, related signalling pathways and induced biological effects. Genesis, differentiation and metastasis of tumours are essentially related to diverse intracellular signalling pathways, such as Jagged/Notch1, TGFβ/SMAD, Wnt/β-Catenin, and FAT/LATS2, which deliver multiple signals to the cell nucleus in a cascade mode and then trigger a series of biological effects. miR-650 functions as a tumour promoter or suppressor by posttranscriptionally regulating the pivotal factors (oncogenic or anti-oncogenic) within these cascades to affect various biological processes, including cell cycle arrest, proliferation, apoptosis, migration, invasion and EMT. The integrated signalling pathways and key factors directly targeted by miR-650 (white blue) are shown

Full size image

miR-650 functions as a tumour promoter

In parallel with the overexpression and clinical features discussed above, miR-650 also conferred more oncogenicity to tumour cells. In HCC, existing evidence indicates that upregulation of miR-650 modulates cell proliferation, apoptosis, migration and invasion [30,31,32, 34] of cancer cells. In terms of the mechanism, miR-650 functions as an upstream signal of the large tumor suppressor kinase 2 gene (LATS2)/YAP (Ser127) signalling pathway and regulates its downstream target genes [30]. Moreover, Ye et al. [64] also revealed that miR-650 could serve as an onco-miR to potentiate cell growth and metastasis by directly targeting LATS2 in NSCLC formation and progression. Interestingly, Liu et al. [46] reported that miR-650 downregulation inhibited proliferation, expedited apoptosis and reduced the migration of HP + GC cells. Moreover, miR-650 mediated the Hippo pathway via the PBX1/miR-650/LATS axis. As a molecular sponge of Axin1, miR-650 enhanced the Wnt signalling pathway to facilitate tumour progression [31]. Furthermore, Ge et al. [32] found that miR-650 in benzo[a]pyrene-exposed cancer cells contributed to HCC metastasis by directly targeting suppressor of cytokine signalling 3 (SOCS3), and this inhibition modulated the activation of the Janus kinase (JAK)/ signal transducer and activator of transcription 3(STAT3) cascade. The study from Zhao et al. [37] suggested that miR-650 silencing inhibited the vital capacity and invasion ability of large-cell carcinomas (LCCs) and lung cancer stem cells (LCSCs) (H1299 cell lines) through the lncRNA maternally expressed gene 3(MEG3)/miR-650/solute carrier family 34 member 2 (SLC34A2) axis. Moreover, ING4 is also a vital gene targeted by miR-650 to facilitate cell proliferation and invasion and induce a stem cell-like state in LC [13, 16]. With regard to CRC, Zhou et al. [40] argued that MIR155HG, as an endogenous lncRNA, competed with annexin 2 (ANXA2) by combining with miR-650, thereby promoting M2 macrophage polarization and oxaliplatin resistance in CRC cells. In another study, decreased luciferase activity of miR-650 was observed with the 3’ untranslated region of N-myc downstream regulated gene 2 (NDRG2) inserted downstream of the luciferase gene, indicating that NDRG2 was directly targeted by miR-650 [65]. Notably, other researchers have observed that inhibition of miR-650 facilitates more apoptosis in CLL cells [59]. Further studies have demonstrated that NDRG2 expression can be significantly downregulated by miR-650 simultaneously with p53 aberrations [59]. It is worth mentioning that other researchers have found that constructed adenoviruses carrying the NDRG2 gene heightened p53-mediated apoptosis of HCC cells [66]. Moreover, CSR1 has also been reported to be a shared gene targeted by miR-650 in both GC [47] and prostate cancer [63]. In addition to cell proliferation and apoptosis, overexpression of miR-650 induces EMT of cancer cells [11, 14, 30, 49, 67], which is a key factor in promoting the metastasis of tumours [68]. Functional analyses in Jin’s study demonstrated that upregulated miR-650 expression heightened the migration of glioma cells through EMT promotion. Additionally, they found that miR-650 could inhibit glioma cell adhesion and promote autophagy. Mechanistically, NF-κB1 upregulated miR-650 expression by directly interacting with its promoter, and then the AKT/ extracellular regulated protein kinases (ERK) and NF-κB pathways were enhanced by miR-650 via the RAS-like, estrogen-regulated growth inhibitor (RERG)-PH domain and leucine rich repeat protein phosphatase 2 (PHLPP2) complex [50].

As a valued member of the ING family, ING4 has been revealed to function as a formidable tumour suppressor due to its significant role in the modification of chromatin modification, cell growth, cell invasion and vascularization [69, 70]. However, it has been revealed to be frequently decreased in various human tumours, and the variation in ING4 markedly contributes to cancer development. Interestingly, accumulating studies have suggested that ING4 is a downstream target of miR-650 in many types of cancer, such as HCC [34], LC [13, 16], CRC [14], GC [15], and BC [60]. Finally, You et al. [14] demonstrated that miR-650 could function as a tumour promoter and enhance the malignant phenotype of CRC. In terms of the mechanism, miR-650 targets ING4, leading to CRC progression promoted by the ERK/p38 mitogen-activated protein kinases (MAPK) pathway. Analogously, another study further suggested that miR-650 increased caspase-3-dependent cell apoptosis by regulating Bcl-2/Bax expression [16] via ING4. Interestingly, Tang et al. [13] revealed that miR-650 promotes NSCLC cell proliferation and migration through the ING4/Wnt-1/β-catenin pathway. Combined, these results suggest that ING4 is a significant regulator of the signalling pathways in the tumorigenic progress of miR-650 and provides promising biomarker and therapeutic target for human cancer.

miR-650 functions as a tumour suppressor

In contrast with the aforementioned investigations, miR-650 has also been reported to function as a tumour suppressor by arresting the cell cycle, inhibiting cell proliferation and weakening the malignant phenotype in tumours. In CRC, there is no consensus about the function of miR-650 thus far. Zhou et al. [39] found that miR-650 inhibited cell growth and migration by suppressing the AKT2/ Glycogen synthase kinase (GSK3β)/E-cadherin pathway. Another bioinformatic study revealed a similar conclusion [41, 42]. Therefore, to further explore the roles of miR-650, more related studies are needed. In addition, rescue experiments in Xu’s et al. [51] study showed that miR-650 could inhibit cell growth by targeting family with sequence similarity 83member F (FAM83F) in glioma. In addition, the lncRNA POU3F3/miR-650/MGMT pathway has been revealed to function critically in DTIC resistance in melanoma [19]. In terms of the mechanism, lncRNA POU3F3 works as a competitive RNA to combine with miR-650; therefore, MGMT expression rises to a higher extent [19] in melanoma cells. Additionally, Liu et al. [56] revealed that miR-650 contained cell proliferation and invasion while exerting on adverse effect on cell apoptosis in cutaneous melanoma via the lncRNA ZFPM2-AS1/miR-650/NOTCH1 axis in melanoma. An article published in Blood indicated that overexpression of miR-650 led to the decreased proliferative capacity of B cells [24]. Mechanistically, miR-650 targeted essential proteins in cell proliferation, namely, cyclin-dependent kinase (CDK1), ING4, and EBF3 in B cells. A cell transfection experiment with miR-650 revealed significant downregulation of signalling molecule levels of EBF3, ING4 and CDK1 by 67%, 64%, and 53%, respectively. This finding validates the correlation of these three proteins with miR-650 in B cells. Moreover, Mraz et al. [24] found that miR-650 was modulated by coupling expression with its homologous gene for immunoglobulin lambda. This observation is surprising because previous studies demonstrated that miR-650 has an independent expression of immunoglobulin [23].

Conclusions

In this review, we discussed the aberrant expression profiles, functions and underlying mechanisms of miR-650 in various cancer tissues and cell lines and focused on its upstream regulators and downstream target genes. As an important member of the miRNA family, miR-650 has been identified to play crucial roles in cancer genesis and progression via diversified signalling molecules, such as ING4, Gfi1, and LATS2, thereby regulating the proliferation, apoptosis, invasion and migration, EMT, and drug resistance of cancer cells. Taken together, accumulating evidence at present suggests that miR-650 can function as a tumour promoter in HCC, LC, GC, BC, EC, ATC, OC, PC, as a tumour suppressor in melanoma, and as both in CRC, glioma, and leukaemia. The discrepancy of its roles in cancer indicates that the functions of miR-650 are influenced by multiple factors, such as cancer cell types and the microecological environment. To fully understand its expressional functions, further studies of miR-650 molecular mechanisms are required.

This overview of the signalling pathways influenced by miR-650 provides us with a more comprehensive understanding of the complex association between miR-650 and human cancer. More significantly, valuable clues regarding the implications of miR-650 based on a constructed lncRNA-miRNA-mRNA molecular network will bring us more effective diagnostic and/or therapeutic strategies for various cancer patients. When arguing the suitability of this miRNA as a biomarker or therapeutic target, researchers need to discuss its availability and detectability in bodily fluid or exosomes and assess the stability in clinical tests.

Availability of data and materials

Not applicable.

Abbreviations

miRNAs:

microRNAs

KRAS:

Kirsten rat sarcoma viral oncogene homologue

PD-1:

Programmed cell death protein 1

EC:

Endometrial cancer

EMT:

Epithelial to mesenchymal transition

ING4:

Inhibitor of growth 4

HCC:

Hepatocellular carcinoma

NASH:

Non-alcoholic steatohepatitis

LC:

Lung cancer

NSCLC:

Non-small-cell lung cancer

LAD:

Lung adenocarcinoma

CRC:

Colorectal cancer

GC:

Gastric cancer

AML:

Acute myeloid leukaemia

EPOR:

Erythropoietin receptor

CLL:

Chronic lymphocyte leukaemia

TTFT:

Time to first treatment

ATC:

Anaplastic thyroid carcinoma

NF:

Nuclear factor

SOCS3:

Suppressor of cytokine signalling 3

LCCs:

Large-cell carcinomas

LCSCs:

Lung cancer stem cells

AXIN1:

Axis inhibition protein 1

CDKN1B:

Cyclin-dependent inhibitor 1B

DTIC:

Dacarbazine

MGMT:

Methylguanine-DNA-methyltransferase

TGF-β:

Transforming growth factor-β

PPP2CA:

Protein Phosphatase 2 Catalytic Subunit Alpha

CSR1:

Cellular stress response

LATS2:

Large tumor suppressor kinase 2 gene

JAK:

Janus kinase

STAT3:

Signal transducer and activator of transcription 3

MEG3:

Maternally expressed gene 3

SLC34A2:

Solute carrier family 34 member 2

ANXA2:

Annexin 2

NDRG2:

N-myc downstream regulated gene 2

ERK:

Extracellular regulated protein kinases

RERG:

Estrogen-regulated growth inhibitor

PHLPP2:

pH domain and leucine rich repeat protein phosphatase 2

MAPK:

Mitogen-activated protein kinases

GSK3β:

Glycogen synthase kinase 3β

FAM83F:

Family with sequence similarity 83member F

CDK1:

Cyclin-dependent kinase

References

  1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.

    PubMed  Google Scholar 

  2. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376:1186–93.

    PubMed  Google Scholar 

  3. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Nagaraju GP, Malla RR, Basha R, Motofei IG. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1. Semin Cancer Biol. 2021. doi:https://doi.org/10.1016/j.semcancer.2021.11.003.

    Article  PubMed  Google Scholar 

  5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47:D155-62.

    Google Scholar 

  7. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5:396–400.

    CAS  PubMed  Google Scholar 

  8. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.

    CAS  PubMed  Google Scholar 

  9. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013;13:109–17.

    PubMed  Google Scholar 

  10. Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20:12.

    PubMed  PubMed Central  Google Scholar 

  11. Gao Q, Huang Q, Li F, Luo F. LncRNA MCTP1-AS1 regulates EMT process in endometrial cancer by targeting the miR-650/SMAD7 Axis. Onco Targets Ther. 2021;14:751–61.

    PubMed  PubMed Central  Google Scholar 

  12. Amano K. Survival and functional results after valve replacement. Kokyu To Junkan. 1990;38:951–61.

    CAS  PubMed  Google Scholar 

  13. Tang X, Ding Y, Wang X, Wang X, Zhao L, Bi H. miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway. Oncol Lett. 2019;18:4621–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. You Q, Li H, Liu Y, Xu Y, Miao S, Yao G, et al. MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling. Oncol Lett. 2018;16:2326–34.

    PubMed  PubMed Central  Google Scholar 

  15. Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun. 2010;395:275–80.

    CAS  PubMed  Google Scholar 

  16. Huang JY, Cui SY, Chen YT, Song HZ, Huang GC, Feng B, et al. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS ONE. 2013;8:e72615.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Hernández-Aguilar JA, Cortina-Villar HS, García-Barrios LE, Castillo-Santiago M. Factors limiting formation of community forestry enterprises in the Southern Mixteca region of Oaxaca, Mexico. Environ Manage. 2017;59:490–504.

    PubMed  Google Scholar 

  18. Yun JH, Moon S, Lee HS, Hwang MY, Kim YJ, Yu HY, et al. MicroRNA-650 in a copy number-variable region regulates the production of interleukin 6 in human osteosarcoma cells. Oncol Lett. 2015;10:2603–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Wu K, Wang Q, Liu YL, Xiang Z, Wang QQ, Yin L, et al. LncRNA POU3F3 contributes to dacarbazine resistance of human melanoma through the MiR-650/MGMT axis. Front Oncol. 2021;11:643613.

    PubMed  PubMed Central  Google Scholar 

  20. Qu W, Jiang L, Hou G. Circ-AFF2/miR-650/CNP axis promotes proliferation, inflammatory response, migration, and invasion of rheumatoid arthritis synovial fibroblasts. J Orthop Surg Res. 2021;16:165.

    PubMed  PubMed Central  Google Scholar 

  21. Xu X, Chen H, Zhang Q, Xu J, Shi Q, Wang M. MiR-650 inhibits proliferation, migration and invasion of rheumatoid arthritis synovial fibroblasts by targeting AKT2. Biomed Pharmacother. 2017;88:535–41.

    CAS  PubMed  Google Scholar 

  22. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci USA. 2006;103:3687–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Das S. Evolutionary origin and genomic organization of micro-RNA genes in immunoglobulin lambda variable region gene family. Mol Biol Evol. 2009;26:1179–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012;119:2110–3.

    CAS  PubMed  Google Scholar 

  25. Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10:2993–3036.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Li C, Chen K, Liu X, Liu HT, Liang XM, Liang GL, et al. Analysis of clinicopathological characteristics and prognosis of young patients with hepatocellular carcinoma after hepatectomy. J Clin Transl Hepatol. 2020;8:285–91.

    PubMed  PubMed Central  Google Scholar 

  27. Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021. doi:https://doi.org/10.1038/s41571-021-00573-2.

    Article  PubMed  Google Scholar 

  28. Chao X, Wang S, Fulte S, Ma X, Ahamed F, Cui W, et al. Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy. J Hepatol. 2021. doi:https://doi.org/10.1016/j.jhep.2021.10.014.

    Article  PubMed  Google Scholar 

  29. Wang Y, Kui L, Wang G. Combination therapy for HCC: from CRISPR screening to the design of clinical therapies. Signal Transduct Target Ther. 2021;6:359.

    PubMed  PubMed Central  Google Scholar 

  30. Han LL, Yin XR, Zhang SQ. miR-650 promotes the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by directly inhibiting LATS2 expression. Cell Physiol Biochem. 2018;51:1179–92.

    CAS  PubMed  Google Scholar 

  31. Qin A, Wu J, Zhai M, Lu Y, Huang B, Lu X, et al. Axin1 inhibits proliferation, invasion, migration and EMT of hepatocellular carcinoma by targeting miR-650. Am J Transl Res. 2020;12:1114–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Ge Y, Gu P, Wang W, Cao L, Zhang L, Li J, et al. Benzo[a]pyrene stimulates miR-650 expression to promote the pathogenesis of fatty liver disease and hepatocellular carcinoma via SOCS3/JAK/STAT3 cascades. J Mol Cell Biol. 2021. doi:https://doi.org/10.1093/jmcb/mjab052:mjab052.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Matboli M, Gadallah SH, Rashed WM, Hasanin AH, Essawy N, Ghanem HM, et al. mRNA-miRNA-lncRNA regulatory network in nonalcoholic fatty liver disease. Int J Mol Sci. 2021;22:6770.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Zeng ZL, Li FJ, Gao F, Sun DS, Yao L. Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol. 2013;107:105–10.

    CAS  PubMed  Google Scholar 

  35. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

    PubMed  Google Scholar 

  36. Black RC, Khurshid H. NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance. R I Med J (2013). 2015;98:25–8.

    Google Scholar 

  37. Zhao Y, Zhu Z, Shi S, Wang J, Li N. Long non-coding RNA MEG3 regulates migration and invasion of lung cancer stem cells via miR-650/SLC34A2 axis. Biomed Pharmacother. 2019;120:109457.

    CAS  PubMed  Google Scholar 

  38. Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell. 2012;21:448.e2.

    PubMed  Google Scholar 

  39. Zhou C, Cui F, Li J, Wang D, Wei Y, Wu Y, et al. MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway. Oncotarget. 2017;8:49534.

    PubMed  PubMed Central  Google Scholar 

  40. Zhou L, Li J, Liao M, Zhang Q, Yang M. LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2. Cancer Immunol Immunother. 2021. doi:https://doi.org/10.1007/s00262-021-03055-7.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Slattery ML, Mullany LE, Sakoda L, Samowitz WS, Wolff RK, Stevens JR, et al. The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol. 2018;144:269–83.

    CAS  PubMed  Google Scholar 

  42. Feng L, Xie Y, Zhang H, Wu Y. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun. 2011;406:534–8.

    CAS  PubMed  Google Scholar 

  43. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    PubMed  Google Scholar 

  44. Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534–42.

    PubMed  Google Scholar 

  45. Chen J, Wu L, Sun Y, Luo C, Chen X, Wu L, et al. Diagnostic value and clinical significance of circulating miR-650 and CA211 in detecting of gastric carcinoma. Oncol Lett. 2020;20:254.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Liu J, Wang L, Li J, Xu Y. Upregulation of microRNA-650 by PBX1 is correlated with the development of Helicobacter pylori-associated gastric carcinoma. Neoplasma. 2021;68:262–72.

    PubMed  Google Scholar 

  47. An J, Guo X, Yan B. DICER-AS1 functions as competing endogenous RNA that targets CSR1 by sponging microRNA-650 and suppresses gastric cancer progression. J Int Med Res. 2021;49:3000605211041466.

    CAS  PubMed  Google Scholar 

  48. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

    PubMed  Google Scholar 

  49. Sun B, Pu B, Chu D, Chu X, Li W, Wei D. MicroRNA-650 expression in glioma is associated with prognosis of patients. J Neurooncol. 2013;115:375–80.

    CAS  PubMed  Google Scholar 

  50. Jin S, Li X, Dai Y, Li C, Wang D. NF-κB-mediated miR-650 plays oncogenic roles and activates AKT/ERK/NF-κB pathways by targeting RERG in glioma cells. Cell Oncol (Dordr). 2020;43:1035–48.

    CAS  Google Scholar 

  51. Xu L, Yu QW, Fang SQ, Zheng YK, Qi JC. MiR-650 inhibits the progression of glioma by targeting FAM83F. Eur Rev Med Pharmacol Sci. 2018;22:8391–8.

    CAS  PubMed  Google Scholar 

  52. Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, McCubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (Review). Int J Oncol. 2018;52:1071–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Hartman RI, Lin JY. Cutaneous melanoma-A review in detection, staging, and management. Hematol Oncol Clin North Am. 2019;33:25–38.

    PubMed  Google Scholar 

  54. Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986–2016. Am J Public Health. 2020;110:731–3.

    PubMed  PubMed Central  Google Scholar 

  55. Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019;20:1135–52.

    PubMed  Google Scholar 

  56. Liu W, Hu X, Mu X, Tian Q, Gao T, Ge R, et al. ZFPM2-AS1 facilitates cell proliferation and migration in cutaneous malignant melanoma through modulating miR-650/NOTCH1 signaling. Dermatol Ther. 2021;34:e14751.

    CAS  PubMed  Google Scholar 

  57. Yuan C, Xu L, Du P, Pang J. miRNA-650 exerts anti-leukemia activity by inhibiting cell proliferation through Gfi1 targeting. Tumori. 2018;104:369–74.

    CAS  PubMed  Google Scholar 

  58. Gaine ME, Sharpe DJ, Smith JS, Colyer HAA, Hodges VM, Lappin TR, et al. GATA2 regulates the erythropoietin receptor in t(12;21) ALL. Oncotarget. 2017;8:66061–74.

    PubMed  PubMed Central  Google Scholar 

  59. Yang YQ, Tian T, Zhu HY, Liang JH, Wu W, Wu JZ, et al. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia. BMC Cancer. 2018;18:1009.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Lango-Chavarría M, Chimal-Ramírez GK, Ruiz-Tachiquín ME, Espinoza-Sánchez NA, Suárez-Arriaga MC, Fuentes-Pananá EM. A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients. Int J Oncol. 2017;50:432–40.

    PubMed  PubMed Central  Google Scholar 

  61. Orlandella FM, Mariniello RM, Iervolino PLC, Imperlini E, Mandola A, Verde A, et al. miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine. 2019;65:582–94.

    CAS  PubMed  Google Scholar 

  62. Ningning S, Libo S, Chuanbin W, Haijiang S, Qing Z. MiR-650 regulates the proliferation, migration and invasion of human oral cancer by targeting growth factor independent 1 (Gfi1). Biochimie. 2019;156:69–78.

    PubMed  Google Scholar 

  63. Zuo ZH, Yu YP, Ding Y, Liu S, Martin A, Tseng G, et al. Oncogenic activity of miR-650 in prostate cancer is mediated by suppression of CSR1 expression. Am J Pathol. 2015;185:1991–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Ye Y, Zhuang J, Wang G, He S, Ni J, Xia W, et al. microRNA-605 promotes cell proliferation, migration and invasion in non-small cell lung cancer by directly targeting LATS2. Exp Ther Med. 2017;14:867–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. O’Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, et al. Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS ONE. 2012;7:e48895.

    PubMed  PubMed Central  Google Scholar 

  66. Cao W, Zhang JL, Feng DY, Liu XW, Li Y, Wang LF, et al. The effect of adenovirus-conjugated NDRG2 on p53-mediated apoptosis of hepatocarcinoma cells through attenuation of nucleotide excision repair capacity. Biomaterials. 2014;35:993–1003.

    CAS  PubMed  Google Scholar 

  67. Schwartz HI, Vingiano W, Perez CB. Autonomy and the right to refuse treatment: patients’ attitudes after involuntary medication. Hosp Commun Psychiatry. 1988;39:1049–54.

    CAS  Google Scholar 

  68. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15:18.

    PubMed  PubMed Central  Google Scholar 

  69. Cui S, Gao Y, Zhang K, Chen J, Wang R, Chen L. The emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancers. Cell Physiol Biochem. 2015;36:409–22.

    CAS  PubMed  Google Scholar 

  70. Yan R, He L, Li Z, Han X, Liang J, Si W, et al. SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer. Genes Dev. 2015;29:672–85.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was funded by the National Nature Science Foundation of China (U20A20343) and the Independent Project Fund of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the National Key Research and Development Program of China (2016YFC1101404/3).

Author information

Author notes

  1. Yuanshuai Su and Qiuxian Zheng contributed equally to this work

Authors and Affiliations

  1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, National Clinical Research Center for Infectious Diseases, Zhejiang University, Hangzhou, 310003, China

    Yuanshuai Su, Qiuxian Zheng, Lingxiao Zhu, Xinyu Gu, Juan Lu & Lanjuan Li

Authors
  1. Yuanshuai Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiuxian Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingxiao Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinyu Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lanjuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LL and JL designed and guided the study. YS and QZ wrote and edited the manuscript. LZ and XG helped with reference collection. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Juan Lu or Lanjuan Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Su, Y., Zheng, Q., Zhu, L. et al. Functions and underlying mechanisms of miR-650 in human cancers. Cancer Cell Int 22, 132 (2022). https://doi.org/10.1186/s12935-022-02551-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-022-02551-9

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us